IL42495A - Ocular hypotensive composition containing d-isoproterenol - Google Patents
Ocular hypotensive composition containing d-isoproterenolInfo
- Publication number
- IL42495A IL42495A IL42495A IL4249573A IL42495A IL 42495 A IL42495 A IL 42495A IL 42495 A IL42495 A IL 42495A IL 4249573 A IL4249573 A IL 4249573A IL 42495 A IL42495 A IL 42495A
- Authority
- IL
- Israel
- Prior art keywords
- isoproterenol
- salt
- ophthalmologically acceptable
- amount
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (23)
1. An ophthalmologically acceptable composition containing an effective intraocular pressure lowering amount of cl-isoproterenol or ophthalmologically acceptable salt thereof substantially free of 1-isoproterenol or salt thereof.
2. The composition according to Claim 1 comprised of an aqueous solution of a water soluble ophthalmologically . acceptable salt of cl-isoproterenol.
3. The composition according to Claim 2 containing additional ophthalmologically acceptable water soluble ingredients in sufficient amount to yield a substantially isotonic vehicle for said salt of ^-isoprotere ol.
4. K. The composition according to any of Claims 1 to 3 wherein said salt is ^[-isoproterenol tartrate.
5. The composition according to any of Claims 1 to 3 wherein said salt is d_-isoproterenol bitartrate.
6. The composition according to any of Claims 1 to 3 wherein said salt is d-isoproterenol sulfate.
7. The composition according to any of Claims 1 to 3 wherein said salt is d-isoproterenol hydrochloride.
8. A process for lowering intraocular pressure in nonnuman the/mammalian eye characterized by topically applying thereto an effective ophthalmologically acceptable amount of ^-isoproterenol or an ophthalmologically acceptable salt thereof, substantially free of JL-isoproterenol or salt thereof.
9. . The process of Claim 8 wherein an aqueous solution of a water soluble ophthalmologically acceptable salt of ^-isoproterenol is applied topically.
10. . The process of Claim 9 wherein said solution contains an amount of said water soluble ophthalmologically acceptable salt of ^-isoproterenol equivalent on a molecular basis to from 0 .16$ to 5.2$ by weight of ^-isoproterenol.
11. The process of Claim 9 wherein said solution contains an amount of said water soluble ophthalmologically acceptable salt of ^-isoproterenol which is equivalent on a molecular basis to 0 .16$ to 2 .6$ by weight of ^-isoprote enol.
12. . The process of Claim 9 wherein said solution contains an amount of said water soluble ophthalmologically acceptable salt of d-isoproterenol which is equivalent on a molecular basis to from 0 .6$ to 2 .6$ by weight of d-isoprote enol .
13. . The process of Claims 9 through 12 wherein said solution contains additional ophthalmologically acceptable water soluble ingredients in amounts sufficient to yield a substantially isotonic vehicle for said salt of ^-isoproterenol .
14. . The process of Claims 9 through 13 wherein said salt is d-isoproterenol tartrate. 42495/2
15. The process of claims 9 through 13 wherein said salt is ^-isoproterenol bitartrate.
16. The process of Claims 9 through 13 wherein said salt is ^-isoproterenol sulfate.
17. The process of Claims 9 through 13 wherein said salt is d-isoproterenol hydrochloride.
18. A process for treating glaucoma by instill- nonhuman mammalian ing into the affected/eye a solution containing an effective ophthalmologically acceptable amount of an intraocular pressure lowering drug characterized in that said drug is d-isoproterenol or an ophthalmologically acceptable salt thereof, substantially free of 1-isoproterenol or salt thereof.
19. The process according to claim l8 further characterized in that the ^-isoproterenol or ophthalmologically acceptable salt thereof is instilled in the eye by means of a polymeric ocular insert or soft contact lens.
20. The process according to Claim 19 wherein said insert is insoluble but can absorb tear liquid to form a swollen hydrogel.
21. A composition substantially as hereinbefore described with particular reference to the examples .
22. A process for producing an ophthalmic dosage form having intraocular pressure reducing activity characterized by incorporating into a polymeric insert or soft contact lens an effective ophthalmologicall acceptable amount of <3-isoproperenol or an ophthalmologically acceptable salt thereof, substantially free of 1-isoproterenol or salt thereof.
23. A shaped dosage form produced according to the process of claim 22.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26349672A | 1972-06-16 | 1972-06-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL42495A0 IL42495A0 (en) | 1973-08-29 |
| IL42495A true IL42495A (en) | 1976-02-29 |
Family
ID=23002016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL42495A IL42495A (en) | 1972-06-16 | 1973-06-13 | Ocular hypotensive composition containing d-isoproterenol |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS4948819A (en) |
| BE (1) | BE801020A (en) |
| CA (1) | CA1015663A (en) |
| DD (1) | DD106262A5 (en) |
| DE (1) | DE2330338A1 (en) |
| FR (1) | FR2189032B1 (en) |
| GB (1) | GB1369396A (en) |
| IE (1) | IE37801B1 (en) |
| IL (1) | IL42495A (en) |
| NL (1) | NL7308193A (en) |
| ZA (1) | ZA733953B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8701258D0 (en) * | 1987-03-26 | 1987-03-26 | Pharmacia Ab | A COMPOSITION FOR THE TOPICAL TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION |
| JPS6452727A (en) * | 1988-05-02 | 1989-02-28 | Santen Pharmaceutical Co Ltd | Antiallergic eye drop |
| ZA994264B (en) | 1998-07-01 | 2000-01-25 | Warner Lambert Co | Stereoisomers with high affinity for adrenergic receptors. |
| US7232837B2 (en) | 1999-06-29 | 2007-06-19 | Mcneil-Ppc, Inc. | Stereoisomers with high affinity for adrenergic receptors |
| AU2007231488A1 (en) * | 2006-03-24 | 2007-10-04 | National Research Council Of Canada | Anti-diabetic cataract compounds and their uses |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2070173A1 (en) * | 1969-10-29 | 1971-09-10 | Alcon Lab In | Stabilized aqs pyrocatecholamine prepns |
-
1973
- 1973-05-15 CA CA171,427A patent/CA1015663A/en not_active Expired
- 1973-06-12 ZA ZA733953A patent/ZA733953B/en unknown
- 1973-06-12 GB GB2788973A patent/GB1369396A/en not_active Expired
- 1973-06-13 IL IL42495A patent/IL42495A/en unknown
- 1973-06-13 NL NL7308193A patent/NL7308193A/xx unknown
- 1973-06-14 DE DE2330338A patent/DE2330338A1/en active Pending
- 1973-06-14 FR FR7321591A patent/FR2189032B1/fr not_active Expired
- 1973-06-15 IE IE987/73A patent/IE37801B1/en unknown
- 1973-06-15 JP JP48066976A patent/JPS4948819A/ja active Pending
- 1973-06-15 BE BE132363A patent/BE801020A/en unknown
- 1973-06-15 DD DD171583A patent/DD106262A5/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2189032A1 (en) | 1974-01-25 |
| IL42495A0 (en) | 1973-08-29 |
| IE37801B1 (en) | 1977-10-12 |
| FR2189032B1 (en) | 1977-09-09 |
| CA1015663A (en) | 1977-08-16 |
| ZA733953B (en) | 1974-05-29 |
| AU5642073A (en) | 1974-12-05 |
| JPS4948819A (en) | 1974-05-11 |
| DD106262A5 (en) | 1974-06-12 |
| IE37801L (en) | 1973-12-16 |
| NL7308193A (en) | 1973-12-18 |
| BE801020A (en) | 1973-12-17 |
| DE2330338A1 (en) | 1974-01-03 |
| GB1369396A (en) | 1974-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU629725B2 (en) | Contact lens and process for the manufacture thereof | |
| KR20140076587A (en) | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism | |
| US3843782A (en) | Eye solution and method of using same | |
| Paterson et al. | Intraocular pressure changes after alkali burns | |
| AU4515296A (en) | A method for enhancing outflow of aqueous humor in treatment of glaucoma | |
| IE56177B1 (en) | Celiprolol for the treatment of glaucoma | |
| GB1340515A (en) | Opthalmic solution | |
| Leopold et al. | Effect of diisopropyl fluorophosphate (DFP) on the normal eye | |
| IL42495A (en) | Ocular hypotensive composition containing d-isoproterenol | |
| US3885047A (en) | Ocular hypotensive process employing dextrorotatory phenethanolamines | |
| CN112402372B (en) | Eye drop for delaying treatment of teenager myopia and preparation method thereof | |
| US4510145A (en) | Method for inhibiting contraction of ophthalmic wounds or incisions | |
| PT73152A (en) | Process for preparing a composition to reduce intra-ocular pressure | |
| US3985897A (en) | Ocular hypotensive process employing dextrorotatory sulfonamidophenethanolamines | |
| Seidehamel et al. | Specific hypotensive and antihypertensive ocular effects of d-isoproterenol in rabbits | |
| HURWITZ et al. | Uses of naphazoline (privine®) in ophthalmology | |
| US3920824A (en) | Stable ophthalmic formulation | |
| Williams | Comparison of the accommodative effects of carbachol and pilocarpine with reference to accommodative esotropia. | |
| SUGAR | Evidence for circulation of the aqueous and its relation to glaucoma | |
| US3922348A (en) | 3{40 ,4{40 -Dihydroxy-2-(isopropylamino)acetophenone intraocular pressure lowering process | |
| Calabria et al. | Contact lenses as therapeutic systems | |
| SALMINEN | Effect of oily vehicle on ocular pilocarpine concentration | |
| US3888985A (en) | Method and composition for lowering intraocular pressure | |
| RU2049450C1 (en) | Method for treating ulcerous keratitis | |
| RU2431470C1 (en) | Eye drops |